Philippe JEAN-PIERRE

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/09/2025
• Auteurs : Pierre-Régis BurgelJennifer da SilvaEmmanuelle GirodonIsabelle DurieuMartine Reynaud-GaubertMarlene Murris-EspinRaphael ChironDominique GrenetSophie RamelLaurent MelyRebecca HamidfarBenoit DouvryVéronique HoudouinCamille AudoussetJulie MaceyMarie MittaineLaurence WeissLaure CossonIsabelle Danner-BoucherPhilippe ReixMélisande BaravalleEspérie BurnetIsabelle Sermet-GaudelusClémence MartinJean-Louis PaillasseurClaire AndréjakClaire PouletCinthia RamesPascaline PriouFrançoise TroussierBénédicte Richaud-ThiriezMarie-Laure DalphinAlice LadauradeJulie MaceyClaire BonStephanie BuiMickael FayonKarine CampbellMuriel LauransSylvie MontcouquiolGuillaume LabbeBenoit DouvryRalph EpaudNatascha RemusAnnlyse FantonFrédéric HuetAmale Boldron-GhaddarManuela ScalbertCélia TillardLaurent MelyRébecca HamidfarSébastien QuetantCatherine LlerenaSophie ValoisCamille AudoussetThierry PerezNathalie Wizla-DerambureCaroline ThumerelleMagali Dupuy-GrassetJeanne LanguepinAlexandra Masson-RouchaudIsabelle DurieuRaphaële Nove-JosserandQuitterie ReynaudMaël RichardPhilippe ReixCamille OhlmannThomas PerrinTom ToinMarie-Christine Werck-GalloisMartine Reynaud-GaubertBérengère ColteyNadine Desmazes-DufeuJean-Christophe DubusMélisande BaravalleNathalie StremlerRaphaël ChironFloriane SocchiAnne GuillaumotAurélie TatopoulosSébastien KieferIsabelle Danner-BoucherAdrien TissotTiphaine Roussey-BihoueeMyriam BenhamidaSylvie LeroyWael AlkoussaSarah MarchalPierre-Régis BurgelNicolas CarlierJohanna FesenbeckhIsabelle HonoréReem KanaanClémence MartinIsabelle Sermet-GaudelusFrédérique ChedevergneVéronique HoudouinLaurence Le ClaincheSophie MayerHarriet CorvolSophie DenamurJessica TaytardGuillaume ThouveninKatia Bessaci-KabouyaSandra DuryChantal BelleguicEric DeneuvilleMarie JaminSophie RamelJean Le BihanChristophe MarguetStéphane DominiqueHélène Morisse-PradierStéphanie PramilLaure CoudercElsa GachelinJuliette VerhilleCaroline PerissonRomain KesslerLoïc KassegneMichele PorzioLaurence WeissDominique GrenetSylvie Colin-De-VerdiereSandra de MirandaMarlène Murris-EspinMarion DupuisMarie MittaineLéa RoditisJulie MankikianThomas FlamentLaure CossonCharlotte GirautBaptiste ArnouatAsma GabsiDelphine PouradierAnne-Sophie Bonnel
• Organismes : Institut Cochin AP-HP - Hôpital Cochin AP-HP - Hôpital Cochin Research on Healthcare Performance Assistance Publique - Hôpitaux de Marseille Service Pneumologie-Allergologie [CHU Toulouse] Centre de Ressources et de Compétences en Mucoviscidose [CHU Toulouse] Centre Hospitalier Régional Universitaire [Montpellier] Hôpital Foch [Suresnes] Service de pneumologie [Hôpital Foch] Génétique, génomique fonctionnelle et biotechnologies (UMR 1078) Hôpital Renée Sabran [CHU - HCL] CHU de Grenoble-Alpes - Centre Hospitalier Universitaire CHU Grenoble Centre Hospitalier Intercommunal de Créteil Département de pneumologie pédiatrique [CHU Créteil] AP-HP - Hôpital Robert-Debré [Paris] Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 Centre Hospitalier Régional Universitaire [CHU Lille] Centre Hospitalier Universitaire de Bordeaux Service Gastroentérologie, hépatologie nutrition, diabétologie et maladies héréditaires du métabolisme pédiatrique [CHU Toulouse] Université Paris Cité Centre Hospitalier Régional Universitaire de Tours Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Hospices Civils de Lyon Hôpital Femme Mère Enfant [CHU - HCL] Centre National de la Recherche Scientifique Université Claude Bernard Lyon 1 Université Paris Cité Agents infectieux, résistance et chimiothérapie - UR UPJV 4294 Centre Hospitalier Universitaire d'Amiens-Picardie Research on Healthcare Performance Génétique, génomique fonctionnelle et biotechnologies (UMR 1078)
• Publié dans The Lancet Respiratory Medicine le 23/10/2020

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/09/2025
• Auteurs : Patrick Moretto-CapelleAnthony ScemamaStéphane FaureEszter DudásPierre CafarelliJean-Philippe Champeaux
• Organismes : Interactions Ions-Matière (LCAR) Groupe THEO (LCPQ) Laboratoire Collisions Agrégats Réactivité Interactions Ions-Matière (LCAR) Interactions Ions-Matière (LCAR) Interactions Ions-Matière (LCAR)
• Publié dans Physical Chemistry Chemical Physics le 02/11/2020

---

Résumé :

---

Fichiers liés : Dicationic hydantoin HAL.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/09/2025
• Auteurs : Martin FaureLouis Le BivicMarouane BoukhrisAndrea CianciJean-David BlossierDounia MeddadLucie ChastaingtPhilippe LacroixJérôme JouanPierre-Marie PreuxNicole DarodesVictor AboyansJulien Magne
• Organismes : CHU Limoges Epidémiologie des Maladies Chroniques en zone tropicale Service de cardiologie [CHU Limoges] Service de cardiologie [CHU Limoges] Service de cardiologie [CHU Limoges] Service de cardiologie [CHU Limoges] Epidémiologie des Maladies Chroniques en zone tropicale Epidémiologie des Maladies Chroniques en zone tropicale Service de Chirurgie Thoracique et Vasculaire - Médecine vasculaire [CHU Limoges] Epidémiologie des Maladies Chroniques en zone tropicale Centre Hospitalier Universitaire Dupuytren 1 et 2 CHU Limoges Epidémiologie des Maladies Chroniques en zone tropicale Service de cardiologie [CHU Limoges] Epidémiologie des Maladies Chroniques en zone tropicale Service de cardiologie [CHU Limoges] Université de Limoges Epidémiologie des Maladies Chroniques en zone tropicale
• Publié dans Archives of cardiovascular diseases le 30/10/2020

---

Résumé : Background Due to common pathophysiology and shared risk factors, peripheral artery disease (PAD) is frequently present in patients with calcific aortic stenosis (AS). However, the prevalence of PAD in calcific AS and its prognostic impact require further investigation. Aims To describe the prevalence of PAD in patients with advanced AS requiring intervention and assess the impact of PAD on overall long-term mortality among patients undergoing transcatheter aortic valve replacement (TAVR). Methods All patients who underwent TAVR between 2014 and 2023 in our tertiary care centre were enrolled in a retrospective cohort. PAD was defined by the mention of a clinical diagnosis in medical records, significant arterial stenosis observed on the pre-procedural angio-computed tomography scan or a history of lower-limb revascularization. Results Among the 904 included patients (median [interquartile range] age 84.2 (79.9–87.4) years, 54.4% male), 212 (23.5%) had PAD. Patients with PAD had a significantly higher risk of mortality compared to patients without PAD (mean 5-year survival 40.0%, 95% confidence interval [CI] 32.2–49.6 vs. 52.7%, 95% CI 47.8–58.1; P = 0.008; adjusted hazard ratio [aHR] 1.31, 95% confidence interval [CI] 1.03–1.66; P = 0.029). Among patients without coronary artery disease (CAD), those with PAD alone had an increased risk of mortality (aHR 1.50, 95% CI 1.03–2.21; P = 0.037). Importantly, patients with PAD alone had significantly reduced survival compared to those with CAD alone (i.e. without PAD) (aHR 1.49, 95% CI 1.02-2.19; P = 0.040). However, the survival of patients with both PAD and CAD did not significantly differ from those with CAD without PAD. Conclusion PAD was independently associated with increased mortality in severe calcific AS. Importantly, this excess mortality among patients with PAD was not affected by the simultaneous presence of CAD. Similarly to patients with CAD, patients with AS and concomitant PAD should be considered at high risk of mortality.

---

Fichiers liés : Aortic stenosis.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/09/2025
• Auteurs : Nicolas BonfantiP. CholerJean-Christophe ClementPierre BarréFrançois BaudinLauric CecillonAmélie SaillardWilfried ThuillerJérôme PoulenardNorine KhedimRomain Goury
• Organismes : Environnements, Dynamiques et Territoires de Montagne Centre Alpin de Recherche sur les Réseaux Trophiques et Ecosystèmes Limniques Laboratoire d'Ecologie Alpine Centre Alpin de Recherche sur les Réseaux Trophiques et Ecosystèmes Limniques Laboratoire de géologie de l'ENS Institut des Sciences de la Terre de Paris Laboratoire de géologie de l'ENS Ambassade de France au Kénya Laboratoire d'Ecologie Alpine Laboratoire d'Ecologie Alpine Environnements, Dynamiques et Territoires de Montagne Environnements, Dynamiques et Territoires de Montagne Laboratoire d'Ecologie Alpine
• Publié dans Geoderma le 25/10/2020

---

Résumé : Estimating SOC stocks and stability, as well as modeling their response to rising temperatures, is crucial for predicting climate change impacts. This is particularly true in mountainous regions, where low temperatures slow down SOC decomposition, resulting in higher SOC stocks compared to soils at lower elevations. However, these stocks are also more vulnerable to warming, increasing the risk of SOC depletion. Such conditions create the potential for a positive feedback loop in which warming accelerates SOC losses, further amplifying climate change impacts on these sensitive ecosystems. To better understand the factors controlling SOC stocks and stability in mountain soils, we sampled 170 soil profiles along 29 elevation gradients in the western Alps from 280 to 3160 m a.s.l. We assessed SOC stocks and chemical composition using mid-infrared spectroscopy method and SOC stability with Rock-Eval® thermal analysis. Our findings, based on an unprecedented dataset, reveal a clear elevational pattern in SOC properties. SOC stocks increase with elevation up to the montane belt (1200–1500 m a.s.l.), remain relatively stable through the subalpine zone, and then decline beyond the subalpine/alpine boundary (2200–2400 m a.s.l.). Notably, this transition is also marked by a significant drop in SOC stability, suggesting a shift in the dominant stabilization processes at higher elevations. Our results also indicate that SOC stocks and stability are influenced by a complex interplay of factors. At higher elevations, climate emerges to be the dominant factor, whereas lithology and weathering play a more significant role at lower elevations. These results suggest that at high-elevations, harsh climatic conditions favor stabilization of SOC, while less developed soils limit organo-mineral interactions. In contrast, at warmer, lower elevations with higher carbon fluxes, more developed soils facilitate organo-mineral interactions, thereby enhancing SOC stability in the long term. Consequently, alpine grasslands, which contain substantial stocks of labile carbon stabilized by climatic conditions, appear to be particularly vulnerable to the effects of climate warming.

---

Fichiers liés : 1-s2.0-S0016706125002939-main.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/09/2025
• Auteurs : Pierre NahonClovis Lusivika-NzingaPhilippe MerleFabien ZoulimThomas DecaensNathalie Ganne-CarriéGeorges-Philippe PageauxVincent LeroyLaurent AlricJean-Pierre BronowickiMarc BourlièreJérôme GournayAlbert TranStanislas PolPhilippe MathurinVéronique Loustaud-RattiSophie MétivierVictor de LedinghenArmand AbergelDominique ThabutLouis d'AlterocheMohammed BouattourTarik AsselahDenis OuzanPaul CalesOlivier ChazouillèresMoana Gelu-SimeonDominique RoulotJérôme BoursierCarole CagnotSonia TamazirtAlina PascaleSamuel NilusmasMaïté LewinMarianne ZiolFabrice CarratJean‐charles Duclos-Vallée
• Organismes : Centre de Recherche des Cordeliers Institut Pierre Louis d'Epidémiologie et de Santé Publique Centre de Recherche en Cancérologie de Lyon Centre de Recherche en Cancérologie de Lyon Institute for Advanced Biosciences / Institut pour l'Avancée des Biosciences (Grenoble) AP-HP - Hôpital Avicenne Centre de Recherche des Cordeliers Centre Hospitalier Régional Universitaire [Montpellier] Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB) AP-HP - Hôpital Henri-Mondor Pharmacochimie et Biologie pour le Développement Nutrition-Génétique et Exposition aux Risques Environnementaux Service d'Hépato-gastro-entérologie [CHRU Nancy] Hôpital Saint-Joseph [Marseille] Institut des Maladies de l'Appareil Digestif Centre Hospitalier Régional Universitaire [CHU Lille] Université Côte d'Azur Hôpital l'Archet 2 [Nice] Centre méditerranéen de médecine moléculaire Service d'hépatologie médicale [CHU Cochin] Université Paris Descartes - Paris 5 Institute for Translational Research in Inflammation - U 1286 Biologie moléculaire et cellulaire des microorganismes Service de Bactériologie, Virologie, Hygiène [CHU Limoges] Centre Hospitalier Universitaire de Toulouse Centre Hospitalier Universitaire de Bordeaux Université de Bordeaux CHU Clermont-Ferrand AP-HP - Hôpital de la Pitié Salpêtrière Centre de recherche en épidémiologie et santé des populations Sorbonne Université Centre Hospitalier Régional Universitaire de Tours AP-HP - Hôpital Beaujon Centre de recherche sur l'Inflammation AP-HP - Hôpital Beaujon Centre de recherche sur l'Inflammation Institut Arnault Tzanck Hémodynamique, Interaction Fibrose et Invasivité tumorales Hépatiques Centre Hospitalier Universitaire d'Angers AP-HP - Hôpital Saint-Antoine Institut de recherche en santé, environnement et travail Centre Hospitalier Universitaire de Pointe-à-Pitre / Les Abymes [Guadeloupe] Centre de Recherche des Cordeliers AP-HP - Hôpitaux Universitaires Paris Seine-Saint-Denis Hémodynamique, Interaction Fibrose et Invasivité tumorales Hépatiques Centre Hospitalier Universitaire d'Angers CHU de Grenoble-Alpes - Centre Hospitalier Universitaire CHU Grenoble ANRS - Maladies infectieuses émergentes Physiopathologie et traitement des maladies du foie Physiopathologie et traitement des maladies du foie Institut Pierre Louis d'Epidémiologie et de Santé Publique Centre Hépato-Biliaire [Hôpital Paul Brousse] Assistance publique - Hôpitaux de Paris Centre de Recherche des Cordeliers Institut Pierre Louis d'Epidémiologie et de Santé Publique AP-HP - Hôpital Saint-Antoine Physiopathogénèse et Traitement des Maladies du Foie
• Publié dans Journal of Hepatology le 23/10/2020

---

Résumé : Background & aims: Whether the dynamics of non-invasive tests (NITs) correlate with hepatocellular carcinoma (HCC) risk in patients with cirrhosis following sustained virological response (SVR) remains unknown. Thus, we aimed to describe NIT dynamics and assess their correlation with HCC risk. Methods: The dynamics of NITs (fibrosis-4 index [FIB-4], aspartate aminotransferase-to-platelet ratio index [APRI] and liver stiffness measurement) were described in patients with cirrhosis after SVR included in two prospective French multicenter cohorts (ANRS CO22 Hepather and CO12 CirVir) between 2006 and 2015. To assess their relationship with the risk of HCC, a joint modeling approach was employed using both standard and flexible models adjusted for age and sex. The impacts of NIT current value and slope during follow-up on HCC risk were assessed, considering competing risks of death. Results: A total of 3,067 patients with cirrhosis who achieved SVR were analyzed, among whom 228 (7.4%) developed HCC and 210 (6.9%) died during a 26-month follow-up. All NITs were increased at baseline in patients who ultimately developed HCC, whereas platelet counts were lower. All NITs improved in patients who did not develop HCC. More varied changes were observed during the follow-up of patients who ultimately developed HCC. Joint model analyses showed that current values of FIB-4, APRI and platelet count at any time impacted HCC risk. Only FIB-4 and APRI slopes influenced the same outcome. When considering NIT current value and slope simultaneously, only the current value of NITs impacted HCC risk while the slopes were not informative. Conclusions: The dynamics of NITs following SVR do not identify patients with cirrhosis who could be safely excluded from surveillance programs. NIT current value is more informative than slope, which will necessitate regularly re-assessment of HCC risk to design individualized surveillance strategies. Impact and implications: It has been postulated that monitoring non-invasive test (NIT) dynamics following HCV cure may provide information on the residual risk of hepatocellular carcinoma (HCC) in patients with cirrhosis and may allow for the discontinuation of surveillance in certain patient subsets. We analyzed data from over 3,000 patients and found that while all NITs improved in patients with cirrhosis who did not develop HCC, those who eventually developed liver cancer showed more varied changes in these tests. Specifically, the current values of tests like FIB-4 (fibrosis-4 index) and APRI (aspartate aminotransferase-to-platelet ratio index) were linked to an increased risk of HCC, while their slopes did not provide additional useful information, suggesting that dedicated prospective studies are warranted to define how repeated measurement of NITs could be combined with other variables into HCC risk stratification algorithms. Until then, HCC surveillance should be maintained in all patients with cirrhosis following HCV eradication, even in case of decreased NIT values.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 31/08/2025
• Auteurs : David Messika-ZeitounMichael W.A. ChuDenis BouchardThierry Le TourneauJulien TernaclePhilippe DemersLinrui GuoAngel Yi Nam FuJean Claude DibCharmaine LamThays SokolovAmedeo AnselmiDidier TchétchéOphélie Brault MeslinAnge GoutondjiYoan Lavie-BadiePatrick SeknadjiAugustin CoisneDimitri ArangalageAnne BernardUsha ManianMalek KassAntonio FioreArnaud MaudiereYohann BohbotAurélien SeemannNadjib HammoudiLoïc BièrePierre-Yves LerouxJessica ForcilloAntoine JeuBenjamin ElegamandjiChristine Selton-SutyMartine GilardClaire BouletiOmair ArshadJean-Francois LegareThiziri Si MoussiJian YeCatherine SportouchBindu BittiraLaura MunteFabrice BauerGéraldine OngAli Fatehi HassanabadJordan BernickGeorge WellsRoja GaudaBernard IungWilliam D.T. KentJean-François ObadiaJulien Dreyfus
• Organismes : University of Ottawa Heart Institute Western University [Ontario] Montreal Heart Institute - Institut de Cardiologie de Montréal ITX-lab unité de recherche de l'institut du thorax UMR1087 UMR6291 CHU de Bordeaux Pellegrin [Bordeaux] Montreal Heart Institute - Institut de Cardiologie de Montréal Western University [Ontario] University of Ottawa Heart Institute Clinique Ambroise Paré [Centres Médico-Chirurgicaux Ambroise Paré, Pierre Cherest, Hartmann] University of British Columbia [Canada] Hospices Civils de Lyon Centre Hospitalier Universitaire [Rennes] = Rennes University Hospital [Pontchaillou] Laboratoire Traitement du Signal et de l'Image Clinique Pasteur [Toulouse] Institut Mutualiste de Montsouris Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand Centre Hospitalier Universitaire de Toulouse Hôpital Privé Jacques Cartier [Massy] Centre Hospitalier Régional Universitaire [CHU Lille] Laboratoire de Recherche Vasculaire Translationnelle Centre Hospitalier Régional Universitaire de Tours Membrane Signalling and Inflammation in reperfusion Injuries AP-HP - Hôpital Henri-Mondor Hôpital Saint-Joseph [Marseille] Neurologie [CHU Amiens] Mécanismes physiopathologiques et conséquences des calcifications cardiovasculaires - UR UPJV 7517 Nouvelle Clinique de Tours Saint Gatien-Alliance [Tours] AP-HP - Hôpital de la Pitié Salpêtrière Centre Hospitalier Universitaire d'Angers Médipôle Lyon-Villeurbanne Université de Montréal Hôpital Privé Le Bois Ramsay Santé [Lille] Centre cardiologique du Nord Centre Hospitalier Universitaire de Nancy Hôpital Maison Blanche Centre hospitalier universitaire de Poitiers = Poitiers University Hospital Memorial University of Newfoundland = Université Memorial de Terre-Neuve [St. John's, Canada] Dalhousie University [Halifax] Centre hospitalier Félix-Guyon [Saint-Denis, La Réunion] St. Paul’s Hospital - University of British Columbia [Vancouver, BC, Canada] Clinique du Millénaire - Oc Santé [Montpellier] Health Sciences North Research Institute [Sudbury] AP-HP - Hôpital Européen Georges Pompidou Hôpital Charles Nicolle [Rouen] University of Toronto University of Calgary University of Ottawa Heart Institute University of Ottawa Heart Institute Université d'Ottawa = University of Ottawa [Ontario] AP-HP - Hôpital Bichat - Claude Bernard [Paris] Laboratoire de Recherche Vasculaire Translationnelle University of Calgary Hospices Civils de Lyon Centre cardiologique du Nord
• Publié dans Circulation le 29/10/2020

---

Résumé : Background: Comprehensive knowledge of the clinical presentation, contemporary management, and outcomes on "allcomer" patients referred for mitral valve surgery (MVS) are critical to evaluate current practice and adherence to guidelines, understand selection biases, and inform key stakeholders on quality improvement. Methods: MITRACURE is a large international retrospective registry of consecutive adult patients who underwent isolated or combined MVS for mitral regurgitation (MR) in France or Canada in 2019 with in-depth clinical and echocardiographic characterization. Patients operated on for isolated mitral stenosis or who had a prior mitral valve intervention were excluded. Data were obtained from detailed chart abstraction and were site reported. Results: In 2019, 3522 patients underwent MVS (48% combined) across 40 centers (88±46 MVSs/center, median 80, interquartile [51–131]). Mean age was 65±12 years, and 35% were women. The most common MR etiology was myxomatous (61%), followed by functional (9%), infective endocarditis (9%), and rheumatic disease (7%). MR quantification was performed in only 43%. Advanced clinical presentation was common: 43% were in New York Heart Association class III/IV, 30% exhibited congestive heart failure, 47% were on diuretics, 22% had atrial fibrillation/flutter, 35% presented with reduced ejection fraction, and 22% had pulmonary hypertension (≥50 mm Hg). Most patients were symptomatic or presented with class I/IIa indication for intervention, and an early intervention was performed only in 3% of patients. The repair rate was 62% overall and 80% in myxomatous disease. In-hospital mortality was 4.5% overall but 2.3% in patients with myxomatous MR (1.8% isolated, 3.1% combined). Conclusions: MITRACURE provides a contemporary, multicenter, "real-world" picture of the clinical presentation, management, and in-hospital outcomes of MVS for MR in two Western countries. Patients were often referred late in the disease process, with few patients undergoing early intervention. The higher mortality and lower repair rates reported may be more reflective of an unselected MR patient population but have room for improvement. Our results underline the need to develop strategies to improve management and outcomes of patients with MR.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 29/08/2025
• Auteurs : Line Carolle Ntandja WandjiMohamed Bou SalehCyril SobolewskiMehdi El AmraniFabrice BrayEmmanuel BoleslawskiJérôme EeckhoutePierre-Jean DevauxFrançois MaggiottoSolenne TarontChristian RolandoViviane GnemmiPhilippe MathurinLaurent DubuquoyAlexandre Louvet
• Organismes : Institute for Translational Research in Inflammation - U 1286 Institute for Translational Research in Inflammation - U 1286 Institute for Translational Research in Inflammation - U 1286 Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 Miniaturisation pour la Synthèse, l’Analyse et la Protéomique - UAR 3290 Thérapies Assistées par Lasers et Immunothérapies pour l'Oncologie - U 1189 Institut Européen de Génomique du Diabète - European Genomic Institute for Diabetes - FR 3508 Institute for Translational Research in Inflammation - U 1286 Institute for Translational Research in Inflammation - U 1286 Institute for Translational Research in Inflammation - U 1286 Université de Rouen Normandie Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 Institute for Translational Research in Inflammation - U 1286 Institute for Translational Research in Inflammation - U 1286
• Publié dans JHEP Reports Innovation in Hepatology le 07/09/2020

---

Fichiers liés : PIIS2589555925002629.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 28/08/2025
• Auteurs : Marie AndréJulien KirchgesnerDavid LaharieLucas GuilloPhilippe SeksikLaurent AbramowitzMathurin FumeryPauline WilsMorgane AmilStéphane NanceyCatherine Le BerreA. BuissonNadia FathallahCyrielle Gilletta de Saint JosephMathieu UzzanDriffa MoussataNicolas DuveauLaurent Peyrin‐BirouletStéphane NahonNicolas RichardMaeva CharkaouiÉric VicautLucine Vuitton
• Organismes : Centre Hospitalier Régional Universitaire de Besançon Pharmacoépidémiologie et évaluation des soins [iPLesp] AP-HP - Hôpital Saint-Antoine Hôpital Haut-Lévêque [CHU Bordeaux] Université de Bordeaux Hôpital Nord [CHU - APHM] Aix Marseille Université Centre de Recherche Saint-Antoine AP-HP - Hôpital Saint-Antoine AP-HP - Hôpital Bichat - Claude Bernard [Paris] Centre Hospitalier Universitaire d'Amiens-Picardie Périnatalité et Risques Toxiques - UMR INERIS_I 1 UPJV Hôpital Claude Huriez [Lille] Université de Lille Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon Centre International de Recherche en Infectiologie Centre Hospitalier Lyon Sud [CHU - HCL] Institut des maladies de l'appareil digestif [Nantes] Centre d’Investigation Clinique de Nantes Centre Hospitalier Universitaire de Nantes = Nantes University Hospital CHU Clermont-Ferrand Hôpital Léopold Bellan Centre hospitalier Saint-Joseph [Paris] Centre Hospitalier Universitaire de Toulouse AP-HP - Hôpital Henri-Mondor Université Paris-Est Créteil Val-de-Marne - Paris 12 Membrane Signalling and Inflammation in reperfusion Injuries Centre Hospitalier Régional Universitaire de Tours Centre Hospitalier de Roubaix Nutrition-Génétique et Exposition aux Risques Environnementaux Service d'Hépato-gastro-entérologie [CHRU Nancy] Groupe Hospitalier Intercommunal Le Raincy-Montfermeil Nutrition, Inflammation et axe Microbiote-Intestin-Cerveau Université de Rouen Normandie Service d'Hépato-Gastroentérologie [CHU Rouen] Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand AP-HP - Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal Centre Hospitalier Régional Universitaire de Besançon Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098)
• Publié dans The American Journal of Gastroenterology le 22/10/2020

---

Résumé : INTRODUCTION: Intravenous infliximab (IFX) is the cornerstone for treating patients with perianal Crohn's disease (pCD). Data on the recently launched subcutaneous (SC) IFX for pCD are limited. The aim of our study was to evaluate the effectiveness and safety of SC IFX in pCD. METHODS: We conducted a multicenter retrospective cohort study from the GETAID, including patients with either active (group 1) or inactive (group 2) pCD when they started SC IFX. Inclusion criteria were, for group 1: active pCD in the 6 months before initiation of SC IFX; for group 2: inactive pCD for >6 months at the time of IV to SC switch. The primary end points were clinical remission at 6 months in group 1 and pCD relapse in group 2. RESULTS: Of the 183 patients included in 24 centers, 66 were in group 1 and 117 in group 2. The median follow-up was 50.4 (27.0–64.6) and 53.4 (40.6–67) weeks, respectively. In group 1 at 6 months, clinical remission was observed in 44.6% of patients and clinical response in 87.7%. Clinical remission including seton removal occurred in 35.5% of patients. In multivariable analysis, high body mass index was the only independent predictor of remission (odds ratio 0.88, 95% confidence interval 0.77–0.99). In group 2, rates of relapse-free survival were 94.3% and 87.9% at 6 and 12 months, respectively. Sixteen cases (8.3%) of adverse events related to SC injection were observed. DISCUSSION: SC IFX was effective and safe for the treatment of active pCD and for maintaining remission after switching in this large multicenter cohort, thus supporting its use in routine practice in this indication.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 28/08/2025
• Auteurs : Vincent GuiraudAntoine FauchoisCathia SouliéValentin LeducqMarianne VeyriLambert AssoumouDavid BoutolleauDominique CostagliolaOlivier LambotteJean-Philippe SpanoValérie PourcherAnne-Geneviève MarcelinVincent Calvez
• Organismes : Institut Pierre Louis d'Epidémiologie et de Santé Publique AP-HP - Hôpital de la Pitié Salpêtrière Institut Pierre Louis d'Epidémiologie et de Santé Publique AP-HP - Hôpital de la Pitié Salpêtrière Institut Pierre Louis d'Epidémiologie et de Santé Publique AP-HP - Hôpital de la Pitié Salpêtrière Institut Pierre Louis d'Epidémiologie et de Santé Publique AP-HP - Hôpital de la Pitié Salpêtrière Institut Pierre Louis d'Epidémiologie et de Santé Publique AP-HP - Hôpital de la Pitié Salpêtrière Institut Pierre Louis d'Epidémiologie et de Santé Publique Institut Pierre Louis d'Epidémiologie et de Santé Publique AP-HP - Hôpital de la Pitié Salpêtrière Institut Pierre Louis d'Epidémiologie et de Santé Publique Institut Pierre Louis d'Epidémiologie et de Santé Publique Institut Pierre Louis d'Epidémiologie et de Santé Publique AP-HP - Hôpital de la Pitié Salpêtrière Institut Pierre Louis d'Epidémiologie et de Santé Publique AP-HP - Hôpital de la Pitié Salpêtrière Institut Pierre Louis d'Epidémiologie et de Santé Publique AP-HP - Hôpital de la Pitié Salpêtrière
• Publié dans Scientific Reports le 26/10/2020

---

Résumé : Antibodies to programmed cell death 1 (PD-1), Programmed death-ligand 1 (PDL-1) and Cytotoxic-T-lymphocyte-associated protein 4 (CTLA-4) can revert HIV latency and enhance anti-HIV cytotoxic response but their impact on HIV proviral sequences and integration landscape in people with HIV (PWH) remain to be studied. Two PWH treated with PD-1/PDL-1 and one with PD-1/CTLA4 were studied among the ANRS-CO-24 OncoVIHAC cohort study. Matched integration site and proviral sequencing were performed pre-and post-treatment. Immune checkpoint inhibitors (ICI) were not associated with significant changes in total cellassociated HIV-DNA, nor significant changes in genomic or epigenetic features of integration sites. ICIs were associated with a lesser proportion of proviruses with pol frameshifts for all regimen, with the PD-1 and PD-1/CTLA4 patients also experiencing a higher proportion of proviral sequences harboring gag frameshifts and a higher number of STOP codons, consistent with a gag-driven immune clearance. ICI use were consistently associated with a limited reduction in the HIV-reservoir diversity. Finally, the patient with a PD-1/CTLA4 treatment exhibited the loss of an HIV-clone in the NIN-oncogene representing 17% of all his pre-treatment sequences. Despite stable levels of cell-associated HIV DNA, ICI treatment can lead to modest changes in proviral sequence landscapes.

---

Fichiers liés : OncoVIHAC-papier-revised-unmarked.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 27/08/2025
• Auteurs : Ariel GraykowskiGuillaume LanginDavid ChironBruno GuilletF. MarchisNicolas BiverGérard ArlicBernard BaudouinEtienne BertrandRandall BlakeCyrille BosquetJohn BradleyIsabelle BrocardChristophe CacAlain CagnaNicolas CastelEric ChariotOlivier ClergetTom CoarraseLucas CogniauxJulien CollotChristophe CotéMichel DeconinckJean-Paul DesgreesJ. DesmarsGiuseppe Di TommasoJosé DonasWilliam DrapeaudTodd ForresterFlorent FremontKeiichi FukuiPaul GardeJérôme GaudillierePascal GaudinAlexis GiacomoniDavid GinestePatrice GirardJean Claude GomezChuck GoodmanGerard-Philippe GrandjeanPhilippe GuiglionDavid HavellPatrick HuthKachi IwaiMarc-Etienne JulienRachel KnightRyuichi KukitaPetri KuossariJean-Michel LadruzeAnis Ben LassouedCédric LatgéJean-Marie LaugierMatthieu LauvernierPatrice Le GuenJean-Charles Le TarnecDidier LefoulonLiouba LerouxNiniane LerouxArnaud LeroyChelsey LoganYohann LorandElisabeth MarisJean-Pierre MasiniNicola MeneghelliLaurent MillartEric MinyMike MitchellBaptiste MontoyaFabrice MortecretteAnouchka NardiAntoine NgoDenis NicolasRaphael NicolleratTakaya OkadaWataru OnoGeorge PatatoukasJacqueline Payet-AyraultPatrick PicardClaude PorchelKanai PottsMichel QuienenMartial RelierFabien RichardotDarren RivettMatthew RynoFadi SaibiSophie SaibiChristian SartiniHiromichi SasakiPhilippe SeibertMasao ShimizuLucas SifoniGeorges SimardPetri TikkanenIan TransomBernard TregonFrank TyrlikLaurent VadrotMichel VeuilletChristian VoirolStefan WillCorine YahiaPhil YehleNeil YoblonskyWai-Chun Yue
• Organismes : Search for Extraterrestrial Intelligence Institute Association Française d'Astronomie Club Eclipse : Club d'Etudes du Ciel, de la Lune, des Instruments, des Planètes, du Soleil et des Etoiles... Association Française d'Astronomie Unistellar Search for Extraterrestrial Intelligence Institute Unistellar Observatoire de Paris Association Française d'Astronomie Association Française d'Astronomie Association Française d'Astronomie Unistellar Association Française d'Astronomie Unistellar Unistellar Association Française d'Astronomie Unistellar Unistellar Association Française d'Astronomie Unistellar Association Française d'Astronomie Association Française d'Astronomie Unistellar Association Française d'Astronomie Association Française d'Astronomie Association Française d'Astronomie Institut Polytechnique des Sciences Avancées Laboratoire Temps Espace Unistellar Unistellar Association Française d'Astronomie Unistellar Association Française d'Astronomie Unistellar Unistellar Association Française d'Astronomie Unistellar Association Française d'Astronomie Association Française d'Astronomie Unistellar Association Française d'Astronomie Unistellar Association Française d'Astronomie Unistellar Unistellar Unistellar Unistellar Association Française d'Astronomie Unistellar Unistellar Unistellar Unistellar Association Française d'Astronomie Association Française d'Astronomie Unistellar Association Française d'Astronomie Unistellar Association Française d'Astronomie Unistellar Unistellar Association Française d'Astronomie Unistellar Unistellar Association Française d'Astronomie Association Française d'Astronomie Unistellar Unistellar Unistellar Unistellar Unistellar Unistellar Unistellar Association Française d'Astronomie Unistellar Association Française d'Astronomie Unistellar Unistellar Unistellar Association Française d'Astronomie Association Française d'Astronomie Association Française d'Astronomie Unistellar Association Française d'Astronomie Association Française d'Astronomie Unistellar Unistellar Unistellar Unistellar Unistellar Association Française d'Astronomie Unistellar Association Française d'Astronomie Unistellar Association Française d'Astronomie Unistellar Unistellar Unistellar Association Française d'Astronomie Association Française d'Astronomie Association Française d'Astronomie Association Française d'Astronomie Association Française d'Astronomie Unistellar Association Française d'Astronomie Unistellar Unistellar Unistellar
• Publié dans The Planetary Science Journal le 01/11/2020

---

Résumé : We report photometric observations of Comet 103P/Hartley 2 during its 2023 apparition. Our campaign, conducted from August through December 2023, combined data from a global network of citizen astronomers coordinated by Unistellar and the Association Française d'Astronomie. Photometry was derived using an automated pipeline for eVscope observations in partnership with the SETI Institute and aperture photometry via AstroLab Stellar. We find that the comet's peak reduced brightness, measured at G min = 10.24 ± 0.47, continues a long-term fading trend since 1991. The decline in activity follows a per-apparition minimum magnitude increase of ∆G min = 0.59 ± 0.11 mag, corresponding to a ∼42% reduction in brightness each return. This trend implies that the comet's active fraction has declined by approximately an order of magnitude since 1991 and may indicate that Hartley 2 is no longer hyperactive by definition. The fading is consistent with progressive volatile depletion rather than orbital effects. These results offer insight into the evolutionary processes shaping Jupiter-family comets.

---

Fichiers liés : 2508.20215v1.pdf

---

Source